Global spending on drugs to slow through 2016

by LINDA A. JOHNSON

(AP) — Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with slower increases in what those countries spend on brand-name drugs, according to a new forecast.

But from 2012 through 2016, the pharmaceutical industry will sharply boost its sales in emerging markets including China, India and Russia, according to the report from data firm IMS Health, which collects and analyzes data on pharmaceutical sales around the world.

The company's latest forecast on global medicine sales and trends predicts total will rise from about $956 billion in 2011 to just under $1.2 trillion in 2016, based on reported wholesale drug prices. However, IMS estimates the undisclosed rebates and discounts drug companies give to commercial and government prescription plans, a strategy to win more of their business, reduce the actual cost by about 15 percent. That would put total pharmaceutical spending at about $1 trillion in 2016.

Spending will grow at "historically low levels" in the U.S. and might even decline by a percent in Europe, the report says.

The report also says the U.S. share of the world's prescription drug spending will drop from about 41 percent in 2006 and 34 percent last year to 31 percent in 2016. Spending by emerging markets will jump from 14 percent of the total in 2006 to 30 percent in 2016. By 2016, the U.S. will be spending about $892 a year on medicines for an estimated 326 million people, compared to $420 a person in Canada, $121 per person in China and $33 a year per person in India.

"We're going to see the cost of medicines drop dramatically in the U.S." because of all the new generic drugs, said Michael Kleinrock, head of research development at the IMS Institute for Healthcare Informatics.

This year alone, patent expirations will bring new generic competition in the U.S. for nearly 10 blockbusters with $1 billion or more in global annual sales. Those include Singulair for asthma and allergies, Plavix for stroke prevention, high blood pressure Diovan, Lexapro for depression and anxiety, osteoporosis treatment Boniva and two medicines for schizophrenia and other serious psychiatric disorders, Seroquel and Geodon.

More than two dozen other big sellers are set to get generic competition from 2013 through 2016. Over six months or so, the prices for generics usually drop by 80 percent or 90 percent from the brand-name price.

Kleinrock noted that about 80 percent of the prescriptions filled in the U.S. now are generics, and he expects that to hit about 85 percent by 2016.

Besides encouraging use of generics, which are generally the only medicines affordable in poor countries, government health programs, particularly in debt-laden European countries, have been pressing drugmakers for lower prices, he said.

More information: www.theimsinstitute.org

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Data firm sees 2011 drug sales rising 5-7 percent

Oct 07, 2010

(AP) -- Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm ...

Americans turn to generic medications in 2010: report

Apr 22, 2011

(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Drug prices to plummet in wave of expiring patents

Jul 25, 2011

The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top ...

Ranbaxy CEO planning expansion in US, elsewhere

Jul 10, 2012

(AP) — The head of Indian drugmaker Ranbaxy Laboratories Ltd. says he's charging ahead with plans to expand sales in the crucial U.S. market, despite extra oversight from American regulators over quality questions that ...

Recommended for you

Xtoro approved for swimmer's ear

9 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

10 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.